Exelixis, Inc.
Index- P/E23.11 EPS (ttm)0.84 Insider Own1.40% Shs Outstand321.12M Perf Week-9.48%
Market Cap6.19B Forward P/E17.86 EPS next Y1.09 Insider Trans-5.89% Shs Float315.31M Perf Month-8.76%
Income272.60M PEG0.50 EPS next Q0.22 Inst Own88.30% Short Float2.69% Perf Quarter-1.62%
Sales1.55B P/S3.98 EPS this Y103.90% Inst Trans1.82% Short Ratio2.96 Perf Half Y2.91%
Book/sh7.45 P/B2.61 EPS next Y19.23% ROA10.30% Target Price27.54 Perf Year8.40%
Cash/sh4.83 P/C4.03 EPS next 5Y46.00% ROE12.10% 52W Range15.50 - 23.40 Perf YTD6.56%
Dividend- P/FCF19.95 EPS past 5Y35.40% ROI10.10% 52W High-16.75% Beta0.60
Dividend %- Quick Ratio6.00 Sales past 5Y49.60% Gross Margin96.70% 52W Low25.68% ATR0.84
Employees954 Current Ratio6.10 Sales Q/Q8.90% Oper. Margin21.60% RSI (14)36.84 Volatility5.87% 3.59%
OptionableYes Debt/Eq0.00 EPS Q/Q-26.90% Profit Margin17.50% Rel Volume1.05 Prev Close19.23
ShortableYes LT Debt/Eq0.00 EarningsAug 09 AMC Payout0.00% Avg Volume2.86M Price19.48
Recom1.90 SMA20-7.76% SMA50-4.89% SMA200-1.74% Volume2,991,553 Change1.30%
Jun-24-22Initiated BMO Capital Markets Outperform $28
Nov-19-21Initiated Piper Sandler Overweight $34
Nov-03-21Resumed Jefferies Buy $28
Oct-07-21Initiated Jefferies Buy $28
Aug-06-21Reiterated H.C. Wainwright Buy $35 → $64
Jun-15-21Initiated H.C. Wainwright Buy $47
May-18-21Resumed Goldman Sell $23
Mar-31-21Initiated Credit Suisse Outperform $30
Mar-12-21Initiated Wolfe Research Outperform $35
Mar-04-20Initiated Barclays Overweight $26
Jan-13-20Initiated SunTrust Buy $31
Nov-13-19Initiated BofA/Merrill Buy $22
Mar-18-19Upgrade Morgan Stanley Underweight → Equal-Weight
Sep-17-18Initiated Goldman Neutral $22
Sep-10-18Initiated Morgan Stanley Underweight $19
May-11-18Reiterated Needham Buy $33 → $30
Oct-17-17Reiterated RBC Capital Mkts Outperform $33 → $39
Oct-17-17Reiterated Needham Buy $30 → $33
Oct-16-17Reiterated SunTrust Buy $32 → $35
Sep-22-17Downgrade Leerink Partners Outperform → Mkt Perform
Aug-14-22 01:20AM  
Aug-13-22 10:23AM  
Aug-12-22 08:20AM  
Aug-10-22 04:20PM  
Aug-09-22 08:42PM  
Aug-08-22 09:14AM  
Aug-06-22 10:23AM  
Aug-02-22 10:01AM  
Aug-01-22 12:29PM  
Jul-29-22 08:54AM  
Jul-28-22 05:55AM  
Jul-26-22 04:05PM  
Jul-25-22 10:43AM  
Jul-22-22 10:45AM  
Jul-21-22 05:25PM  
Jul-12-22 11:57AM  
Jul-11-22 08:00AM  
Jul-07-22 11:30AM  
Jul-05-22 04:05PM  
Jul-01-22 09:40AM  
Jun-26-22 06:45AM  
Jun-24-22 10:45AM  
Jun-23-22 05:06AM  
Jun-22-22 12:26PM  
Jun-21-22 08:00AM  
Jun-17-22 11:31AM  
Jun-16-22 09:33AM  
Jun-09-22 11:30AM  
Jun-08-22 05:21AM  
Jun-05-22 08:57AM  
Jun-01-22 09:45AM  
May-31-22 04:05PM  
May-27-22 10:10AM  
May-26-22 05:00PM  
May-21-22 07:05AM  
May-18-22 10:23AM  
May-17-22 11:00AM  
May-13-22 10:41AM  
May-11-22 02:08PM  
May-10-22 05:25PM  
May-09-22 08:48AM  
May-04-22 04:05PM  
May-03-22 09:22AM  
Apr-29-22 09:40AM  
Apr-26-22 04:05PM  
Apr-25-22 04:42PM  
Apr-21-22 05:17PM  
Apr-20-22 12:55PM  
Apr-19-22 11:50AM  
Apr-18-22 12:45PM  
Apr-14-22 08:00AM  
Apr-13-22 04:05PM  
Apr-12-22 10:36AM  
Apr-07-22 12:25PM  
Apr-01-22 05:51AM  
Mar-29-22 11:15AM  
Mar-25-22 01:41PM  
Mar-16-22 12:32PM  
Mar-15-22 12:03PM  
Mar-14-22 04:05PM  
Mar-11-22 06:30AM  
Mar-02-22 04:05PM  
Feb-25-22 05:06AM  
Feb-20-22 06:58AM  
Feb-18-22 12:44PM  
Feb-17-22 05:15PM  
Feb-16-22 09:11AM  
Feb-15-22 09:14AM  
Feb-10-22 03:01PM  
Feb-07-22 03:28PM  
Feb-04-22 05:38PM  
Feb-03-22 04:05PM  
Feb-02-22 04:05PM  
Jan-26-22 05:38PM  
Jan-20-22 05:06AM  
Jan-18-22 05:30PM  
Jan-11-22 04:03AM  
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Senner Christopher J.EVP and CFOAug 11Option Exercise6.21225,0001,397,250670,882Aug 12 08:23 PM
Haley Patrick J.EVP, CommercialMay 27Sale18.2118,812342,567239,818Jun 01 08:28 PM
WILLSEY LANCEDirectorMay 12Option Exercise3.1340,000125,200464,415May 13 08:10 PM
WILLSEY LANCEDirectorMay 12Sale19.6540,000786,000424,415May 13 08:10 PM
WYSZOMIERSKI JACK LDirectorApr 04Option Exercise3.1340,000125,200279,888Apr 06 08:08 PM
WYSZOMIERSKI JACK LDirectorApr 04Sale23.006,696154,008273,192Apr 06 08:08 PM
Haley Patrick J.EVP, CommercialApr 01Option Exercise6.2110,00062,100279,191Apr 04 08:11 PM
Haley Patrick J.EVP, CommercialApr 01Sale23.0010,000230,000269,191Apr 04 08:11 PM
Haley Patrick J.EVP, CommercialMar 31Option Exercise6.2110,00062,100279,191Apr 04 08:11 PM
Haley Patrick J.EVP, CommercialMar 31Sale22.4310,000224,300269,191Apr 04 08:11 PM
Hessekiel JeffreyEVP, General Counsel & SecMar 29Sale22.0013,283292,226605,236Mar 30 08:17 PM
Hessekiel JeffreyEVP, General Counsel & SecMar 28Sale22.004,717103,774618,519Mar 30 08:17 PM
Garber Alan MDirectorMar 01Option Exercise3.1340,000125,20052,718Mar 03 08:07 PM
Garber Alan MDirectorMar 01Sale21.0021,301447,32131,417Mar 03 08:07 PM
Haley Patrick J.EVP, CommercialFeb 25Sale19.5331,238610,078198,476Feb 28 08:09 PM
Hessekiel JeffreyEVP and General CounselFeb 24Sale20.0018,000360,000555,361Feb 28 08:11 PM
FELDBAUM CARL BDirectorFeb 22Option Exercise3.1320,00062,60028,521Feb 24 08:20 PM
PAPADOPOULOS STELIOSDirectorFeb 22Sale19.5684,5151,653,1131,220,036Feb 24 08:22 PM
FELDBAUM CARL BDirectorFeb 22Sale19.4920,000389,8008,521Feb 24 08:20 PM
Haley Patrick J.EVP, CommercialFeb 03Option Exercise1.9060,000114,000305,241Feb 04 09:52 PM
Haley Patrick J.EVP, CommercialFeb 03Sale17.9160,0001,074,600245,241Feb 04 09:52 PM
Lamb PeterEVP, Scientific Strategy & CSODec 15Option Exercise6.2147,500294,975410,672Dec 17 08:35 PM
Lamb PeterEVP, Scientific Strategy & CSODec 15Sale17.4447,500828,400363,172Dec 17 08:35 PM
Haley Patrick J.EVP, CommercialNov 24Sale17.2517,236297,321237,802Nov 26 07:39 PM
FELDBAUM CARL BDirectorNov 19Option Exercise3.1320,00062,60028,521Nov 23 08:11 PM
FELDBAUM CARL BDirectorNov 19Sale17.6220,000352,4008,521Nov 23 08:11 PM
Lamb PeterEVP, Scientific Strategy & CSONov 15Option Exercise6.2147,500294,975458,740Nov 17 08:02 PM
Lamb PeterEVP, Scientific Strategy & CSONov 15Sale18.0947,500859,275411,240Nov 17 08:02 PM
Hessekiel JeffreyEVP and General CounselNov 01Sale22.035,117112,728632,825Nov 03 08:12 PM
Lamb PeterEVP, Scientific Strategy & CSOOct 15Option Exercise6.2147,500294,975458,740Oct 15 08:15 PM
Lamb PeterEVP, Scientific Strategy & CSOOct 15Sale21.9247,5001,041,200411,240Oct 15 08:15 PM
Hessekiel JeffreyEVP and General CounselOct 15Sale22.0212,883283,684637,942Oct 15 08:14 PM
Senner Christopher J.EVP and CFOSep 21Option Exercise3.6690,000329,400446,591Sep 23 08:16 PM
Haley Patrick J.EVP, CommercialSep 16Option Exercise1.7025,00042,500305,994Sep 17 07:58 PM
Haley Patrick J.EVP, CommercialSep 16Sale20.3625,000509,000280,994Sep 17 07:58 PM
Lamb PeterEVP, Scientific Strategy & CSOSep 15Option Exercise6.2147,500294,975436,967Sep 17 07:56 PM
Lamb PeterEVP, Scientific Strategy & CSOSep 15Sale20.4647,500971,850389,467Sep 17 07:56 PM
Lamb PeterEVP, Scientific Strategy & CSOAug 16Option Exercise1.9055,000104,500444,467Aug 18 07:56 PM
Lamb PeterEVP, Scientific Strategy & CSOAug 16Sale18.4455,0001,014,200389,467Aug 18 07:56 PM